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Abstract
ICP0 is a regulatory protein that plays a critical role in the replication-latency balance of herpes simplex virus (HSV). Absence
of ICP0 renders HSV prone to establish quiescent infections, and thus cellular repressor(s) are believed to silence HSV mRNA
synthesis when ICP0 fails to accumulate. To date, an ICP0-antagonized repressor has not been identified that restricts HSV
mRNA synthesis by more than 2-fold. We report the unexpected discovery that HSV’s major transcriptional regulator, ICP4,
meets the criteria of a bona fide ICP0-antagonized repressor of viral mRNA synthesis. Our study began when we noted a
repressive activity that restricted ICP0 mRNA synthesis by up to 30-fold in the absence of ICP0. When ICP0 accumulated, the
repressor only restricted ICP0 mRNA synthesis by 3-fold. ICP4 proved to be necessary and sufficient to repress ICP0 mRNA
synthesis, and did so in an ICP4-binding-site-dependent manner. ICP4 co-immunoprecipitated with FLAG-tagged ICP0; thus,
a physical interaction likely explains how ICP0 antagonizes ICP4’s capacity to silence the ICP0 gene. These findings suggest
that ICP0 mRNA synthesis is differentially regulated in HSV-infected cells by the virus-encoded repressor activity embedded
in ICP4, and a virus-encoded antirepressor, ICP0. Bacteriophage l relies on a similar repression-antirepression regulatory
scheme to ‘‘decide’’ whether a given infection will be productive or silent. Therefore, our findings appear to add to the
growing list of inexplicable similarities that point to a common evolutionary ancestry between the herpesviruses and tailed
bacteriophage.
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Introduction
During productive replication, ,75 proteins are synthesized
from the herpes simplex virus (HSV) genome in a temporal
cascade [1]. Virion protein 16 (VP16) in the tegument of HSV
virions forms a complex with the cellular transcription factor Oct 1
to initiate a cascade of viral gene expression [2,3]. Only five
immediate-early (IE) genes are initially induced based on the
presence of VP16-responsive elements in their promoters [4]. Viral
IE proteins such as infected cell proteins 0 (ICP0) and 4 (ICP4) are
believed to play a key role in activating viral mRNA synthesis, and
thus promoting the synthesis of ,70 early (E) and late (L) proteins
that replicate and package HSV genomes into new virions.
ICP0 was first identified based on its capacity to transform
HSV’s major transcriptional regulator, ICP4, from a weak
transcriptional activator to a potent activator of mRNA synthesis;
specifically, combinations of ICP0 and ICP4 are 20-fold more
potent at driving mRNA synthesis than either ICP0 or ICP4 alone
[5,6]. Functionally, synthesis of ICP0 causes HSV’s equilibrium to
abruptly tip towards productive replication, whereas absence of
ICP0 produces the opposite effect. Synthesis of ICP0 is sufficient to
trigger HSV reactivation in trigeminal ganglion neurons and other
models of latent HSV infection [7,8]. HSV ICP0
2 viruses replicate
to nearly wild-type levels when cells are inoculated with more than
1 plaque-forming unit (pfu) of virus per cell. At multiplicities of
infection (MOI) below 0.1 pfu per cell, the same ICP0
2 viruses
establish quiescent infections in 99% of the cells they infect [9,10].
Such observations suggest that ICP0 antagonizes a repressor of
HSV replication, whose repressive capacity can be saturated with
high numbers of HSV genomes [10].
Preston and Everett first articulated the concept of an ICP0-
antagonized repressor of HSV gene expression [11,12,13]. Because
ICP0 is an E3 ubiquitin ligase [14], it was suggested that a repressor
might silence HSV mRNA synthesis in the absence of ICP0,
whereas synthesis of ICP0 would result in ubiquitination and/or
proteasomal destruction of the repressor, thus allowing HSV
mRNA synthesis to proceed unhindered [15]. Since the advance-
ment of this hypothesis, many laboratories have joined in the search
for the unidentified repressor(s) of HSV gene expression. Individual
cellular proteins that co-localize with ICP0 have been probed for
their capacity to function as repressors of HSV replication such as
PML and Sp100 [16,17]. Suspected pathways of silencing HSV
genomes, such as epigenetic silencing, have been explored to
determine if HSV ICP0
2 null viruses are more sensitive to these
gene silencing mechanisms [18,19,20,21]. Based on such inquiries,
thelistofproteinsthatmayfunctionasICP0-antagonizedrepressors
of HSV gene expression continues to grow and currently includes
PML [16,17,18,22], Sp100 [23], cyclin D3 [24], IRF-3 and IRF-7
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8837[25], centromeric proteins CENP-B and CENP-C [26,27],
HDAC1/2-CoREST-REST [18], DNA-dependent protein kinase
[28], and class II histone deacetylases [21].
The PML protein is among the most carefully scrutinized of the
potential ICP0-antagonized repressors of HSV replication. In
support of the PML repressor hypothesis, ICP0 and HSV genomes
co-localize with PML nuclear bodies in cells [29,30], synthesis of
ICP0 triggers the dispersal of PML nuclear bodies [29], and PML
is strongly induced by interferon treatments that are known to
impede HSV replication [31]. Weaknesses in the PML repressor
hypothesis include the fact that overexpression of PML does not
inhibit HSV gene expression and does not interfere with the
replication of wild-type HSV or ICP0
2 null viruses [Ref. 32;
unpublished data of W. Halford]. Although siRNA-knockdown of
both PML and Sp100 results in an ,40-fold increase in the
replication of HSV ICP0
2 null viruses in human fibroblasts, this
represents less than a 1% complementation of the .10,000-fold
repression that occurs in these cells [17]. Finally, there is no direct
evidence of a physical interaction between ICP0 and PML [33].
Like many laboratories, we too have been interested in
understanding why failure to synthesize ICP0 results in limited
mRNA transcription from the HSV genome. Rather than
interrogate specific proteins for their capacity to repress viral
mRNA synthesis, we chose to establish an experimental system
that would allow us to rapidly monitor repression of a single HSV
IE gene, the ICP0 gene. To this end, an ICP0
2 virus was
constructed that bore an ,750 bp insertion of green fluorescent
protein (GFP) coding sequence and a stop codon in exon 2 of the
ICP0 gene. The resulting virus, HSV-1 0
2GFP, synthesized a
3.5 kb ICP0
2GFP mRNA and a truncated ICP0
2GFP peptide.
Using the GFP fluorescent reporter as a screening tool, we probed
for conditions that alleviated or exacerbated repression of the
ICP0
2GFP reporter gene in HSV-infected cells such as presence or
absence of biologically active ICP0.
With the aid of these new reagents, we report the identification
of a protein that satisfied four empirical criteria that should be
expected of an ICP0-antagonized repressor of HSV mRNA
transcription; specifically, the identified protein 1. was required to
observe repression of ICP0 mRNA synthesis in HSV-infected cells;
2. was sufficient to repress ICP0 mRNA synthesis in the absence of
ICP0; 3. was unable to silence ICP0 mRNA synthesis when ICP0
accumulated; and 4. physically interacted with ICP0.
We report the unexpected finding that the viral IE protein,
ICP4, satisfied all of the criteria expected of a bona fide ICP0-
antagonized repressor of HSV mRNA transcription. It is relevant
to note that ICP4’s capacity to function as a repressor of HSV IE
mRNA transcription is well established, particularly in the context
of the ICP4 and L/ST genes [34,35]. Evidence has been presented
both for and against the hypothesis that ICP4 represses the ICP0
gene in HSV-infected cells [36,37]. However, the perceived
importance of the hypothesis may be measured in terms of the
attention it has received; 14 years have elapsed since the last study
was published that considered ICP4’s potential to repress the ICP0
gene [37].
We present new evidence that corroborates earlier findings that
ICP4’s capacity to repress ICP0 mRNA synthesis is indeed modest
when ICP0 accumulates. However, when ICP0 fails to accumulate,
then ICP4 is capable of silencing the ICP0 gene. We present
functional evidence that ICP0 antagonizes ICP4-dependent
repression of the ICP0 gene. In addition, we present the first
direct evidence that ICP0 and ICP4 physically interact in HSV-
infected cells. Collectively, these data suggest an alternative view of
HSV gene regulation, which is consistent with the biology of a
virus that establishes latent infections: In the absence of ICP0, ICP4
functions as an efficient repressor of HSV IE mRNA transcription, whereas
accumulation of ICP4’s binding partner, ICP0, converts ICP4 from a
repressor to an activator of HSV mRNA synthesis [5,6]. The findings that
led us to these unexpected conclusions are presented below.
Results
Characterization of HSV-1 Viruses That Contain a GFP
Reporter in ICP0
2 or ICP0
+ Genes
HSV-1 recombinant viruses carrying a GFP coding sequence in
each copy of the ICP0 gene were constructed for the purpose of
studying how the ICP0 gene is regulated. An ICP0
+GFP gene was
constructed that encoded an ICP0 protein that bore a GFP
insertion between amino acids 104 and 105 (Fig. 1A). An ICP0-
null control gene, the ICP0
2GFP gene, encoded the N-terminal 104
amino acids of ICP0 fused to GFP (Fig. 1A). The chimeric
ICP0
+GFP or ICP0
2GFP genes were introduced into the LAT-ICP0
locus of HSV-1 strain KOS by homologous recombination to yield
the HSV-1 viruses 0
+GFP and 0
2GFP, respectively (Fig. 1B;
Table 1).
The ICP0
2GFP or ICP0
+GFP reporter proteins encoded by
HSV-1 0
+GFP and 0
2GFP were analyzed by two-color Western
blot analysis. In cells infected with wild-type HSV-1 KOS or
KOS-GFP, ICP0-specific monoclonal antibody 11060 labeled the
110 kDa protein species that is ICP0, as well as two protein species
of ,40 and 55 kDa (red bands, Fig. 1C). In addition, the GFP-
expressing recombinant virus, KOS-GFP [38], encoded an
,30 kDa GFP protein that was labeled by rabbit anti-GFP
antibody (green band in Fig. 1C). As expected, HSV-1 0
2GFP
encoded a single ,55 kDa protein that was labeled by ICP0- and
GFP-specific antibodies, while 0
+GFP encoded an 140 kDa
protein that was labeled with both ICP0- and GFP-specific
antibodies (yellow bands in Fig. 1C).
The functionality of the ICP0
+GFP protein was compared to
wild-type ICP0. Wild-type HSV-1 strain KOS formed plaques
with 100% efficiency in Vero cells relative to the number of
plaques that formed in ICP0-complementing L7 cells (Fig. 1D). In
contrast, only ,1% of HSV-1 0
2GFP (ICP0
2) viruses formed
plaques in Vero cells (Fig. 1D). HSV-1 0
+GFP formed plaques in
Vero cells at 66% efficiency relative to the number of plaques that
formed in ICP0-complementing L7 cells (Fig. 1D). Thus, the
ICP0
+GFP protein retained sufficient activity to promote HSV-1
0
+GFP plaque formation with 45-fold greater efficiency than its
matching ICP0
2 null control virus, HSV-1 0
2GFP.
Inefficient ICP0
2GFP mRNA Synthesis from HSV-1 0
2GFP
in the Absence of ICP0
ICP0 has been described as a promiscuous transcriptional
activator [11,19,39]. We reasoned that ICP0 should act in a
positive-feedback loop to promote mRNA synthesis from its own
gene, the ICP0 gene. To test this inference, an ICP0-expressing
adenovirus vector, Ad-ICP0, was compared to a control vector,
Ad-n212 (Table 2), for its capacity to stimulate the expression of
the ICP0
2GFP reporter gene embedded in the native LAT-ICP0
locus of HSV-1 0
2GFP.
In an initial test, cells were pre-treated with vehicle, Ad-n212, or
Ad-ICP0, and were inoculated 12 hours later with 2.5 pfu per cell
of HSV-1 0
2GFP. When compared at 12 hours post-inoculation
(p.i.), HSV-1 0
2GFP expressed barely detectable levels of
ICP0
2GFP fluorescence in cells pre-treated with vehicle or Ad-
n212 (Fig. 2A). In contrast, pre-treatment with Ad-ICP0 allowed
HSV-1 0
2GFP to express high levels of ICP0
2GFP fluorescence
(Fig. 2A).
HSV Repression-Antirepression
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adenovirus-encoded ICP0 stimulated ICP0
2GFP mRNA accu-
mulation in HSV-1 0
2GFP-infected cells. Vero cells were
inoculated with 0 to 10 pfu per cell of Ad-ICP0, and were
inoculated 12 hours later with 2.5 pfu per cell of HSV-1 0
2GFP.
Northern blot analysis with a GFP-specific probe demons-
trated that Ad-ICP0 stimulated a 5-fold increase in ICP0
2GFP
mRNA levels and did so in a dose-dependent manner (Fig. 2B,
D). In contrast, Ad-n212 had no effect on ICP0
2GFP mRNA
levels (Fig. 2C, D). Therefore, exogenous ICP0 stimulated the
accumulation of ICP0
2GFP mRNA in cells inoculated with
HSV-1 0
2GFP.
Efficient ICP0
2GFP mRNA Synthesis from HSV-1 0
2GFP
when Protein Synthesis Is Blocked
We were interested to determine how ICP0 influences the
activity of the ICP0
2GFP gene in cells inoculated with HSV-1
0
2GFP. One possibility was that ICP0 induced mRNA synthesis
from all of HSV-1 0
2GFP’s genes, including the ICP0
2GFP gene
(Fig. 3A). A second possibility was that absence of ICP0 allowed a
repressor such as PML [17] or HDAC1/2-CoREST-REST [19]
to silence all of HSV-1 0
2GFP’s genes including the ICP0
2GFP
gene (Fig. 3B, red line). Under this latter hypothesis, ICP0
might stimulate ICP0
2GFP mRNA synthesis by antagonizing
the repressor of the ICP0
2GFP gene (Fig. 3B, green line). An
experiment was conducted to evaluate the relative likelihood of
these two possibilities.
The effect of Ad-ICP0 versus Ad-n212 was compared in cells
inoculated with MOIs of 0.1 to 2.0 pfu per cell of HSV-1 0
2GFP.
As expected, HSV-1 0
2GFP expressed ICP0
2GFP mRNA at all
MOIs so long as ICP0 was provided in trans from Ad-ICP0
(Fig. 3C). In cells treated with the Ad-n212 control vector, HSV-1
0
2GFP failed to synthesize detectable levels of ICP0
2GFP mRNA
at MOIs below 0.9 pfu per cell (Fig. 3D). At an MOI of 0.9 pfu per
cell of HSV-1 0
2GFP, 34-fold higher levels of ICP0
2GFP mRNA
were noted in cells treated with Ad-ICP0 relative to cells treated
with Ad-n212 (Fig. 3E). Thus, efficient ICP0
2GFP mRNA
accumulation was highly dependent on ICP0 at low multiplicities
of HSV infection.
The mechanism by which ICP0 promoted ICP0
2GFP mRNA
accumulation was unclear. Two possibilities included ICP0-
dependent induction of ICP0
2GFP mRNA synthesis (Fig. 3A) or
ICP0-dependent antirepression of ICP0
2GFP mRNA synthesis
(Fig. 3B). To differentiate between these possibilities, cells were
inoculated with Ad-ICP0 or Ad-n212 for twelve hours, and then
cells were treated with cycloheximide at the time of HSV-1
0
2GFP inoculation. Thus, Ad-ICP0’s capacity to stimulate
ICP0
2GFP mRNA accumulation could be evaluated in the relative
absence of other activators and/or repressors that formed in HSV-
1 infected cells.
As expected, cells pre-treated with Ad-ICP0 expressed high
levels of ICP0
2GFP mRNA despite the cycloheximide block to the
synthesis of other HSV proteins (Fig. 3F, H). However, to our
surprise, a similar result was observed in Ad-n212-treated cells
treated with cycloheximide (Fig. 3G, H). Thus, when protein
synthesis was blocked in HSV-infected cells, ICP0 was no longer
required for the efficient synthesis of ICP0
2GFP mRNA (Fig. 3G).
These findings argued against the hypothesis that ICP0 was
required to actively induce ICP0
2GFP mRNA synthesis (Fig. 3A).
Rather, the results suggested that ICP0 antagonized a repressor of
the ICP0
2GFP gene that was synthesized de novo in HSV-infected
cells (Fig. 3B, green line). Further tests were conducted to explore
the validity of this hypothesis.
Figure 1. Characterization of HSV-1 0
2GFP and 0
+GFP. (A)
Schematic and (B) Southern blot analysis of the wild-type ICP0,
ICP0
2GFP, and ICP0
+GFP genes in HSV-1 KOS, 0
2GFP, and 0
+GFP,
respectively. Southern blots show an oligonucleotide specific for intron
1 hybridized to a PshAI - BssHII fragment of the ICP0 gene. (C) Two-color
Western blot analysis of proteins harvested from cells that were
uninfected (UI) or were inoculated with 5 pfu per cell of the HSV-1 KOS,
KOS-GFP, 0
2GFP, or 0
+GFP viruses. ICP0 and GFP proteins were labeled
with ICP0-specific monoclonal antibody 11060 (red bands) and rabbit
polyclonal GFP-specific antibody (green bands). Yellow bands are those
in which ICP0 and GFP were present in a single protein. (D) The percent
efficiency of plaque formation cells in Vero cells (i.e., number of plaques
per 100 pfu) of HSV-1 KOS, 0
+GFP, and 0
2GFP, as compared to the
efficiency with which the same viral inocula formed plaques in ICP0-
complementing L7 cells (n=3 per group). As indicated on the
logarithmic scale of the y-axis, HSV-1 0
+GFP and 0
2GFP formed plaques
in Vero cells with 6665% and 1.560.2% efficiency, respectively.
doi:10.1371/journal.pone.0008837.g001
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Model of ICP0 Gene Regulation
Three predictions followed from an hypothesis that HSV-1
ICP0 gene activity was regulated by a process of repression and
antirepression: i. HSV-1 ICP0
2 and ICP0
+ viruses should express
high and equivalent levels of ICP0 mRNA when synthesis of the
repressor was blocked with cycloheximide (Fig. 3B, blue line); ii.
an HSV-1 ICP0
+ virus should efficiently express ICP0 mRNA
when the repressor accumulated in HSV-infected cells (Fig. 3B,
green line); and iii. an HSV-1 ICP0
2 virus should exhibit little to
no ICP0 mRNA synthesis when the repressor accumulated in the
absence of ICP0 (Fig. 3B, red line).
As an initial test of these predictions, the relative expression
of ICP0
2GFP or ICP0
+GFP fluorescent reporter proteins was
compared in cells inoculated with 2.5 pfu per cell of HSV-1
0
2GFP (ICP0
2) versus HSV-1 0
+GFP (ICP0
+). In vehicle-treated
cells, HSV-1 0
2GFP expressed barely detectable levels of
ICP0
2GFP fluorescence, whereas HSV-1 0
+GFP expressed
ICP0
+GFP fluorescence to readily detectable levels (Fig. 4A). In
contrast, when protein synthesis was inhibited for the first 6 hours
of infection with cycloheximide, then both ICP0
2GFP and
ICP0
+GFP fluorescent proteins accumulated to high levels by
6 hours post-release from the cycloheximide block (Fig. 4B).
Quantification by flow cytometry [40] demonstrated that
ICP0
2GFP and ICP0
+GFP fluorescent proteins accumulated to
high and equivalent levels following release from a cycloheximide
block (Fig. S1).
The relative expression of ICP0
2GFP or ICP0
+GFP mRNA was
compared in cells inoculated with HSV-1 0
2GFP versus 0
+GFP.
When protein translation was allowed to occur, HSV-1 0
2GFP
produced levels of ICP0
2GFP mRNA that were barely detectable
between 3 and 12 hours p.i. (Fig. 4C). When cycloheximide was
used to block protein synthesis, ICP0
2GFP mRNA levels
accumulated to levels that were ,90 times background in HSV-
10
2GFP-infected cells (Fig. 4C, E). In contrast, the onset of
protein translation did not prevent an ICP0
+ virus, HSV-1 0
+GFP,
from expressing ICP0
+GFP mRNA to levels that were ,20 times
background (Fig. 4D, E). When protein synthesis was inhibited
with cycloheximide, HSV-1 0
+GFP expressed ,5-fold higher
levels of ICP0
+GFP mRNA (Fig. 4D, E). As predicted, cyclohex-
imide treatment allowed HSV-1 0
2GFP and 0
+GFP to express
high and equivalent levels of ICP0
GFP mRNA (Fig. 4E). Control
experiments verified that cycloheximide blocked HSV-1 L mRNA
synthesis (i.e., glycoprotein D mRNA), but had only a negligible
effect on cellular GAPDH mRNA levels (Fig. S2).
These findings were consistent with the predictions of a
repression-antirepression model of ICP0 gene regulation (Fig. 3B).
However, questions remained about the identity of the de novo
repressor that inhibited ICP0 mRNA synthesis in HSV-1 0
2GFP-
infected cells. Alternatively, it was possible that cycloheximide
stimulated synthesis of all HSV mRNAs including ICP0
2GFP
mRNA in a non-specific manner [41]. Further experiments were
conducted to differentiate between these possibilities.
Table 1. Description of HSV-1 viruses.
Virus/Genotype Phenotype/Properties Reference
KOS (wild-type) Wild-type laboratory strain of HSV-1 (12 passages removed from isolation). [84]
n212 (ICP0
2 null) Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 211 of 775 amino acids of ICP0. [43]
0
2GFP (ICP0
2 null) Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 104 amino acids of ICP0 coupled
to GFP.
this study
0
24BS
2 (ICP0
2 null) Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 104 amino acids of ICP0 coupled
to GFP. A 4-bp deletion disrupts the ICP4 DNA-binding site in the ICP0 promoter.
this study
0
+GFP (ICP0
+) Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-length ICP0 with GFP inserted
between amino acids 104 and 105.
this study
0
+4BS
2 (ICP0
+) Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-length ICP0 with GFP inserted
between amino acids 104 and 105. A 4-bp deletion disrupts the ICP4 DNA-binding site in the ICP0 promoter.
this study
0
+FLAG24 (ICP0
+) Replicates with 100% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-length ICP0 with FLAG epitope
inserted between amino acids 23 and 24.
this study
RP4 (VP16
2 null) Replicates with 1% efficiency at MOIs ,0.1 pfu per cell; virus synthesizes VP16 protein lacking half of the acidic
transactivation domain (Da.a. 413–454 [of 490]).
[44]
n12 (ICP4
2 null) Incapable of replication unless ICP4 is provided in trans; virus synthesizes the first 252 of 1298 amino acids of ICP4. [50]
tsB21 (ICP4
ts) Replication-competent at 34u; replication-defective at 39.5uC; virus synthesizes a temperature-sensitive ICP4 protein
(lesion maps to the C-terminal third).
[47]
d27-1 (ICP27
2 null) Incapable of replication unless ICP27 is provided in trans; virus bears a 1.6 kb deletion that removes 80% of the
ICP27 ORF.
[48]
22/n199 (ICP22
2 null) Virus replicates like wild-type in cell culture but fails to replicate in animals; virus synthesizes the first 198 of 420 amino
acids of ICP22.
[49]
doi:10.1371/journal.pone.0008837.t001
Table 2. Description of DE1–E3 adenovirus vectors.
Virus Promoter/Gene product Reference
Ad-null TRE promoter/no gene product [7]
Ad-ICP0 TRE promoter/wild-type ICP0
(775 amino acids)
[7]
Ad-n212 TRE promoter/N-terminus of ICP0
(211 of 775 amino acids)
[7]
Ad-ICP4 TRE promoter/wild-type ICP4
(1298 amino acids)
[7]
Ad.CMV-TetOn CMV promoter/TetOn (rtTA) protein [7]
doi:10.1371/journal.pone.0008837.t002
HSV Repression-Antirepression
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VP16-Dependent Manner
VP16 carried in HSV virions binds six VP16-responsive
elements in the ICP0 promoter at the outset of infection
(Fig. 5A), and thus VP16 induces ICP0 mRNA synthesis [2,42].
An experiment was conducted to determine if cycloheximide’s
effect on steady-state ICP0 mRNA levels was the result of a VP16-
dependent process, or rather was due to a myriad of non-specific
effects that should operate with equal efficiency in the presence or
absence of VP16.
ICP0 mRNA accumulation was compared in cells inoculated
with 2.5 pfu per cell of wild-type HSV-1 KOS, the ICP0
2 virus
n212 [43], or the VP16
2 virus RP4 [44] (Table 1). When protein
synthesis was allowed to occur, wild-type HSV-1 expressed ICP0
mRNA to levels that were 28-fold above background, whereas an
ICP0
2 virus and VP16
2 virus expressed ICP0 mRNA to levels that
were only 4-fold above background (Fig. 5B, C). When protein
synthesis was blocked with cycloheximide, the VP16
+ viruses
exhibited a robust increase in ICP0 mRNA levels; consequently,
wild-type HSV and the ICP0
2 virus expressed high and equivalent
levels of ICP0 mRNA in cycloheximide-treated cells (Fig. 5B, C).
In contrast, the VP16
2 virus failed to efficiently express ICP0
mRNA in either vehicle- or cycloheximide-treated cells (Fig. 5C).
Thus, cycloheximide was incapable of stimulating ICP0 mRNA
accumulation in the absence of VP16. These data argued against
the possibilities that cycloheximide might increase ICP0 mRNA
abundance by 1. decreasing the rate of ICP0 mRNA turnover, or
by 2. stimulating a non-specific increase in the rate of transcription
of all genes, including the ICP0 gene. Rather, the data were
consistent with an hypothesis that cycloheximide blocked the
formation of a de novo repressor of the ICP0 gene that was
dominant over the HSV-specific inducer of the ICP0 gene, VP16.
De Novo Repression of HSV ICP0 Gene Expression Is
ICP4-Dependent
There is evidence that inhibition of protein synthesis causes all
of HSV’s IE mRNAs to be overexpressed [45]. One interpretation
that has been offered is that cycloheximide’s effect on HSV
mRNA synthesis is global and non-specific [41]. However, there is
a second, biologically important hypothesis that has not been
adequately considered. As well as HSV ICP4’s function as an
essential activator of E and L mRNA transcription [46], ICP4 may
function as a repressor of IE mRNA transcription [47]. To
determine if ICP4 contributed to de novo repression of the ICP0
gene, ICP0 mRNA accumulation was compared in cells
inoculated with HSV-1 mutants deficient in the IE regulatory
proteins ICP0, ICP27, ICP22, or ICP4 (Table 1).
Regardless of their different genotypes, 2.5 pfu per cell of each
HSV-1 VP16
+ virus yielded high and equivalent levels of ICP0
mRNA in cycloheximide-treated cultures (Fig. 6A). The ICP0
2
virus, n212, expressed very low levels of ICP0 mRNA when
protein translation was allowed to occur, whereas each of the
ICP0
+ viruses expressed ICP0 mRNA to levels that were readily
detectable in vehicle-treated cells (Fig. 6A). Wild-type HSV-1
KOS expressed 3.560.4-fold lower levels of ICP0 mRNA in
vehicle-treated cells relative to cycloheximide-treated controls
(Fig. 6A, B). Likewise, the ICP27
2 and ICP22
2 viruses, d27-1 [48]
and 22/n199 [49], expressed 4- to 5-fold less ICP0 mRNA in
vehicle-treated cells relative to cycloheximide-treated controls
(Fig. 6A, B). These results suggested that the de novo repressor of
ICP0 mRNA synthesis formed efficiently in the absence of ICP22,
ICP27, or the ,70 HSV E and L proteins whose synthesis was
ICP27-dependent [48]. In contrast, an ICP4
2 virus, n12 [50],
Figure 2. ICP0 stimulates HSV ICP0
2GFP gene expression. (A)
Photomicrographs of ICP0
2GFP protein fluorescence in Vero cells
inoculated with 2.5 pfu per cell of HSV-1 0
2GFP at 12 hours p.i., which
were pre-treated with either vehicle or 10 pfu per cell of Ad-n212 or Ad-
ICP0 for 12 hours (206magnification). The TRE promoters in Ad-n212
and Ad-ICP0 were induced with 20 pfu per cell of Ad.CMV-TetOn and
10 mM doxycycline. (B and C) Northern blot comparison of ICP0
2GFP
mRNA levels in cells that were uninfected (UI) or were inoculated with
2.5 pfu per cell of HSV-1 0
2GFP and 0 to 10 pfu per cell of (B) Ad-ICP0 or
(C) Ad-n212 (10 mg RNA per lane; RNA harvested at 12 hours p.i.). (D)
ICP0
2GFP mRNA levels plotted as a function of the MOI of adenovirus in
the pre-treatment.
doi:10.1371/journal.pone.0008837.g002
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and cycloheximide-treated cells (Fig. 6A, B). Therefore, de novo
repression of ICP0 mRNA accumulation appeared to be
dependent upon the synthesis of ICP4.
An independent test was conducted to corroborate this
interpretation. Vero cells were inoculated with 2.5 pfu per cell
of HSV-1 KOS (ICP4
+) or HSV-1 tsB21 (ICP4
ts), which bears a
temperature-sensitive lesion in the C-terminus of ICP4; this
mutation renders ICP4 non-functional at a temperature of
39.5uC [47]. At 34.0u,3 7 . 0 u, and 39.5uC, wild-type HSV-1
KOS expressed ,3-fold less ICP0 mRNA in vehicle-treated
cells relative to cycloheximide-treated controls (Fig. 6C, D).
Figure 3. ICP0 de-represses HSV ICP0
2GFP gene expression. (A and B) Alternative models by which ICP0 may stimulate ICP0
2GFP gene activity.
(A) An ICP0 induction model predicts that ICP0 will be required to induce the ICP0
2GFP gene to its full activity (green line), whereas efficient ICP0
2GFP
gene expression will not occur in the absence of ICP0 (blue line). (B) An ICP0 antirepression model predicts that i. a repressor will silence the ICP0
2GFP
gene when ICP0 fails to accumulate (red line), ii. ICP0 prevents the repressor from silencing the ICP0
2GFP gene (green line), and iii. ICP0 is not required
for efficient ICP0
2GFP gene expression when the repressor is absent (blue line). (C, D, F, G) Northern blots of ICP0
2GFP mRNA isolated from Vero cells
inoculated with MOIs of 0.1 to 2 pfu per cell of HSV-1 0
2GFP (RNA harvested 12 hours p.i.; 10 mg per lane). Vero cells were pre-treated with 10 pfu per
cell of (C, F) Ad-ICP0 or (D, G) Ad-n212 whose TRE promoters were induced with 20 pfu per cell of Ad.CMV-TetOn and 10 mM doxycycline. Cells were
treated with (C, D) vehicle or (F, G) 200 mM cycloheximide at the time of HSV-1 0
2GFP inoculation. (E, H) ICP0
2GFP mRNA levels are plotted as a
function of the MOI of HSV-1 0
2GFP used to inoculate Vero cells treated with (E) vehicle or (H) cycloheximide.
doi:10.1371/journal.pone.0008837.g003
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mRNA in vehicle-treated cells at 34.0u and 37.0uC, respectively,
relative to cycloheximide-treated controls (Fig. 6C, D). In
contrast, at the non-permissive temperature of 39.5uC, HSV-1
tsB21 expressed equivalent levels of ICP0 mRNA in both
vehicle- and cycloheximide-treated cells (Fig. 6C, D). Collec-
tively these results indicated that de novo repression of ICP0
mRNA accumulation was dependent upon the synthesis of a
biologically active form of HSV’s major transcriptional regulator,
ICP4.
Figure 4. De novo repression of HSV ICP0
GFP mRNA accumula-
tion is antagonized by a GFP-tagged ICP0 protein. (A and B)
Photomicrographs of ICP0
2GFP and ICP0
+GFP reporter protein fluores-
cence in Vero cells 12 hours after inoculation with 2.5 pfu per cell of
HSV-1 0
2GFP or 0
+GFP (206 magnification). Cells were treated with
either (A) medium containing no drug (vehicle) from 0 to 12 hours p.i.,
or (B) 200 mM cycloheximide from 20.5 to 6 hours p.i. followed by
vehicle from 6 to 12 hours p.i. (C and D) Representative Northern blots
of (C) ICP0
2GFP mRNA or (D) ICP0
+GFP mRNA harvested between 3 and
12 hours after inoculation with 2.5 pfu per cell of HSV-1 0
2GFP or
0
+GFP, respectively. Cells were treated with vehicle or 200 mM
cycloheximide until the indicated time of RNA harvest (10 mg per lane).
(E) Mean6sd of ICP0
2GFP and ICP0
+GFP mRNA levels plotted as a
function of time of RNA harvest (n=2 per time point per group).
doi:10.1371/journal.pone.0008837.g004
Figure 5. Cycloheximide increases ICP0 gene expression in a
VP16-dependent manner. (A) Schematic of ICP0 promoter, which
indicates the positions of six distal VP16-responsive elements (VREs), a
proximal ICP4-binding site (4BS), and the TATA-box of the ICP0 gene. (B)
Representative Northern blot of ICP0 mRNA in Vero cells that were
uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1 KOS,
n212 (ICP0
2), or RP4 (VP16
2), and which were treated with vehicle or
200 mM cycloheximide from 20.5 to 12 hours p.i., at which time total
RNA was harvested (10 mg per lane). (C) Mean 6 sem of ICP0 mRNA
levels in KOS, n212, or RP4-infected cells (n=3 per group). Asterisks
denote significant differences between vehicle- and cycloheximide-
treated cells inoculated with the same virus (p,0.01; two-tailed
Student’s t-test).
doi:10.1371/journal.pone.0008837.g005
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GFP Reporter Genes Is
ICP4-Binding-Site-Dependent
A consensus ICP4-binding site (ATCGTC) occurs 40-bp
upstream of the TATA box in the ICP0 promoter [37,51]. To
determine if ICP4 binding to the ICP0 promoter contributed to de
novo repression of ICP0
GFP mRNA synthesis, the recombinant
viruses HSV-1 0
24BS
2 and 0
+4BS
2 were constructed which were
equivalent to HSV-1 0
2GFP and 0
+GFP, respectively, but which
bore a 4-bp deletion in the ICP4-binding site in the ICP0 promoter
(Fig. 7A).
A test was conducted to determine if disruption of the ICP4-
binding site might alleviate de novo repression of the ICP0
2GFP
gene. Vero cells were inoculated with 5 pfu per cell of HSV-1
0
2GFP or HSV-1 0
24BS
2, and ICP0
2GFP fluorescence was
compared at 12 hours p.i. (Fig. 7B). In cells inoculated with HSV-
10
2GFP, ICP0
2GFP fluorescence was barely visible (Fig. 7B). In
contrast, ICP0
2GFP fluorescence was readily detected in cells
inoculated with HSV-1 0
24BS
2 (Fig. 7B). Likewise, ICP0
+GFP
fluorescence accumulated to appreciably higher levels in cells
inoculated with HSV-1 0
+4BS
2 relative to HSV-1 0
+GFP
(Fig. 7C). These observations suggested that disruption of the
proximal ICP4-binding site in the ICP0 promoter significantly
alleviated de novo repression of the ICP0
2GFP and ICP0
+GFP genes.
To corroborate this interpretation, accumulation of the 3.5 kb
ICP0
GFP RNA species was compared in cells inoculated with 5 pfu
per cell of HSV-1 0
2GFP, 0
24BS
2,0
+GFP, or 0
+4BS
2 (Fig. 7D).
Each virus yielded high levels of ICP0
2GFP or ICP0
+GFP mRNA in
cycloheximide-treated cultures (Fig. 7D). HSV-1 0
2GFP exhibited
a1 3 61-fold repression of ICP0
2GFP mRNA synthesis in vehicle-
treated cells relative to cycloheximide-treated controls (Fig. 7D,
7E). Disruption of the ICP4-binding site in the ICP0 promoter
alleviated de novo repression by 4-fold, and thus HSV-1 0
24BS
2
exhibited only a 3.360.5-fold reduction in ICP0
2GFP mRNA in
vehicle-treated cells (Fig. 7D, 7E). Disruption of the ICP4-binding
site in the ICP0
2GFP gene increased the efficiency of ICP0
GFP
mRNA synthesis to the same extent as synthesis of a biologically
active ICP0 protein; thus, HSV-1 0
24BS
2 and 0
+GFP both
exhibited a 3.3-fold reduction in ICP0
GFP mRNA levels in vehicle-
treated cells relative to their respective cycloheximide-treated
controls (Fig. 7D, 7E). Disruption of the ICP4-binding site in the
ICP0 promoter of HSV-1 0
+4BS
2 resulted in a significant de-
repression; thus ICP0
+GFP mRNA levels in vehicle-treated cells
infected with HSV-1 0
+4BS
2 were only 2.160.2-fold lower than
cycloheximide-treated controls (Fig. 7D, 7E). Collectively, these
observations indicated that the magnitude of de novo repression of
ICP0
GFP mRNA synthesis was significantly dependent upon the
ICP4-binding site proximal to the transcriptional start site of the
ICP0 gene (Fig. 7A).
Adenovirus-Encoded ICP4 Substitutes for the De Novo
Repressor of the HSV ICP0
2GFP Gene
Our results raised the possibility that the de novo repressor of
ICP0 mRNA synthesis was not a cellular protein, but rather was
the HSV ICP4 protein because 1. loss of ICP4 function de-
repressed ICP0 mRNA synthesis to the same extent as
cycloheximide treatment (Fig. 6), and 2. a 4-bp deletion that
removed a single ICP4-binding site significantly alleviated de novo
repression of ICP0 mRNA synthesis (Fig. 7). Based on this
hypothesis, it was predicted that pre-treatment of Vero cells with
an ICP4-expressing adenovirus should negate cycloheximide’s
Figure 6. De novo repression of HSV ICP0 gene expression is ICP4-dependent. (A) Representative Northern blot of ICP0 mRNA in Vero cells
that were uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1 KOS (wild-type), n212 (ICP0
2), dl27-1 (ICP27
2), 22/n199 (ICP22
2), or n12
(ICP4
2), which were treated with vehicle or 200 mM cycloheximide from 20.5 to 6 hours p.i., at which time total RNA was harvested (10 mg per lane).
(B) Mean 6 sem fold-reduction in ICP0 mRNA levels in vehicle-treated cells relative to cycloheximide-treated controls (fold-reduction=mRNACHX4
mRNAVEH; n=4 per group). (C) Representative Northern blot of ICP0 mRNA in Vero cells inoculated with 2.5 pfu per cell of KOS (ICP4
+) or HSV-1 tsB21
(ICP4
ts). Vehicle- and cycloheximide-treated cultures were incubated in CO2 chambers at 34.0, 37.0, or 39.5uC, and total RNA was harvested at
6 hours p.i. (10 mg per lane). (D) Mean 6 sem fold-reduction in ICP0 mRNA levels plotted as a function of incubation temperature (fold-reduction=
mRNACHX4mRNAVEH; n=4 per group). In panels B and D, asterisks denote fold-reductions in ICP0 mRNA that significantly differ from the value of 1,
which is predicted by a null hypothesis that cycloheximide will have no effect on ICP0 mRNA accumulation in HSV-infected cells (p,0.01; two-tailed
Student’s t-test).
doi:10.1371/journal.pone.0008837.g006
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2GFP mRNA synthesis in HSV-1
0
2GFP-infected cells.
To test this prediction, Vero cells were pre-loaded with 0 to 250
pfu per cell of Ad-ICP4 or a null control vector, and cells were
inoculated 12 hours later with HSV-1 0
2GFP in the presence of
cycloheximide. As expected, cells that received no adenovirus
vector and which were inoculated with HSV-1 0
2GFP in the
presence of cycloheximide expressed high levels of ICP0
2GFP
mRNA (Fig. 8A). However, when Vero cells were pre-treated with
Ad-ICP4, cycloheximide’s capacity to stimulate ICP0
2GFP mRNA
synthesis dissipated and this inhibition was adenovirus dose-
dependent (Fig. 8A). Despite cycloheximide treatment, the highest
MOI of Ad-ICP4 caused a 42-fold reduction in ICP0
2GFP mRNA
levels in HSV-1 0
2GFP-infected cells (blue line in Fig. 8C). This
was not a non-specific effect of the adenovirus vector, as MOIs of
10 to 250 pfu per cell of Ad-null did not reduce the efficiency of
ICP0
2GFP mRNA synthesis in HSV-1 0
2GFP-infected cells
treated with cycloheximide (Fig. 8A).
To verify that Ad-ICP4’s capacity to repress ICP0
2GFP mRNA
synthesis was ICP4-binding-site-dependent, the experiment was
performed in parallel with HSV-1 0
24BS
2. Ad-ICP4 had a
modest effect on ICP0
2GFP mRNA synthesis in HSV-1 0
24BS
2-
infected cells (Fig. 8B). However, the potency of inhibition was 10-
fold less than observed in HSV-1 0
2GFP-infected cells (red line in
Fig. 8C). Specifically, an MOI of 250 pfu per cell of Ad-ICP4
produced only a 4.4-fold reduction in ICP0
2GFP mRNA levels in
HSV-1 0
24BS
2-infected cells treated with cycloheximide (Fig. 8C).
Therefore, adenovirus-encoded ICP4 was sufficient to substitute
for the de novo repressor of the ICP0
2GFP gene that routinely
formed in HSV-1 0
2GFP infected cells.
ICP0 Physically Interacts with the Repressor of Its Gene,
ICP4, in HSV-Infected Cells
A physical interaction between ICP0 and ICP4 might begin to
explain how ICP0 influences ICP4’s activity as a transcriptional
regulator. The available evidence from far-Western blotting [52]
and co-localization studies [53] suggested that ICP0 may
physically interact with ICP4. However, direct evidence was
lacking to address whether or not ICP0 and ICP4 physically
interact in the context of HSV-infected cells.
To address this gap in knowledge, a recombinant virus was
constructed that bore a FLAG epitope between amino acids 23
and 24 of ICP0, and which is referred to as HSV-1 0
+FLAG24
(Fig. 9A). Southern blot analysis validated that the FLAG coding
sequence was inserted in both copies of the ICP0 gene, and that
HSV-1 0
+FLAG24 grew with wild-type efficiency (not shown).
Immunofluorescent staining verified that HSV-1 0
+FLAG24
expressed a FLAG-tagged protein that exhibited a nuclear-staining
pattern typical of ICP0 during the IE phase of HSV infection
(Fig. 9B; 10 hours in cycloheximideR6 hours in actinomycin D).
Immunoprecipitation experiments were performed to determine
if ICP4 physically interacted with FLAG-tagged ICP0. Vero cells
were inoculated with vehicle or 5 pfu per cell of HSV-1 KOS or
0
+FLAG24 in the presence of cycloheximide (0–10 hours p.i.)
followed by actinomycin D (10–16 hours p.i.), such that only viral
IE proteins were efficiently synthesized. Input levels of ICP4 and
ICP0 in each immunoprecipitation reaction were equivalent, as
verified by Western blot analysis with monoclonal antibodies 58S
and H1083, respectively (Fig. 9C, top panel). The remainder of
each protein sample was immunoprecipitated with an anti-FLAG
antibody-agarose conjugate under conditions of medium or high
stringency, and immunoprecipitates were analyzed for the
presence of ICP4.
Figure 7. De novo repression of ICP0
GFP gene expression is ICP4-
binding-site-dependent. (A) Schematic of the ICP4 DNA-binding site
(4BS)inHSV-10
2GFPand0
+GFPversusthemutated4BS-elementinHSV-
10
24BS
2 and 0
+4BS
2. All four viruses transcribe 3.5 kb ICP0
GFP mRNAs,
but HSV-1 0
24BS
2 and 0
+4BS
2 are deleted of bases 243 to 240 relative
to the TATA box of the ICP0
GFP gene, which disrupts the consensus ICP4-
binding site, 59-ATCGTC-39. (B and C) Photomicrographs of ICP0
2GFP and
ICP0
+GFP fluorescent protein accumulation in Vero cells 12 hours after
inoculation with 5 pfu per cell of (B) HSV-1 0
2GFP versus 0
24BS
2 or (C)
HSV-1 0
+GFP versus 0
+4BS
2 (206 magnification). (D) Representative
Northern blots of ICP0
GFP mRNA accumulation in Vero cells that were
uninfected (UI) or were inoculated with 5 pfu per cell of HSV-1 0
2GFP
(ICP0
2),0
24BS
2 (ICP0
2),0
+GFP(ICP0
+),or0
+4BS
2 (ICP0
+), andwhichwere
treated with vehicle or 200 mM cycloheximide from 20.5 to 12 hours p.i.,
at which time total RNA was harvested (10 mg per lane). (E) Mean 6 sem
fold-reduction in ICP0
GFP mRNA levels in vehicle-treated cells relative to
cycloheximide-treated controls (fold-reduction=mRNA CHX4mRNA VEH;
n=3 pergroup).Asterisksdenotesignificantdifferencesinfold-reduction
in ICP0
GFP mRNA levels between the ICP0
2 viruses, HSV-1 0
2GFP versus
0
24BS
2 (p,0.001), and between the ICP0
+ viruses, HSV-1 0
+GFP versus
0
+4BS
2 (p,0.01; two-tailed Student’s t-test).
doi:10.1371/journal.pone.0008837.g007
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FLAG-tagged ICP0 from lysates of HSV-1 0
+FLAG24-infected
cells (Fig. 9C, middle panel). Non-specific pull down of ICP4 was
negligible from lysates of uninfected Vero cells or KOS-infected
cells (Fig. 9C). Therefore, the a-FLAG agarose only appeared to
pull down ICP4 when the FLAG epitope was present in ICP0.
Consistent with this interpretation, re-probing of the same blot
with an ICP0-specific monoclonal antibody, H1083, verified that
anti-FLAG agarose efficiently pulled down the 110 kDa FLAG-
tagged ICP0, but did not pull down wild-type ICP0 (Fig. 9C, lower
panel). We conclude that ICP0 and ICP4 do indeed physically
interact in HSV-infected cells, and propose that this interaction is
likely relevant in explaining how ICP0 antagonizes ICP4’s
capacity to silence ICP0 mRNA synthesis from the HSV genome.
Discussion
Identification of an ICP0-Antagonized Repressor of HSV
mRNA Synthesis
HSV routinely establishes latent infections in its human host.
During the latent phase of infection, most of the HSV genome is
transcriptionally silent. It is unclear how the HSV genome is
silenced, but it is generally agreed that synthesis of ICP0
destabilizes repression and thus triggers reactivation of mRNA
synthesis from latent HSV genomes [7,8,54].
The search for an ICP0-antagonized transcriptional repressor
has led investigators to consider the possibility that PML and
Sp100 [17], IRF-3 and IRF-7 [25], and centromere proteins
CENP-B and CENP-C [26,27] may represent the repressors of the
HSV genome that are antagonized by ICP0. Although ICP0 may
alter the subcellular distribution, stability, or function of these
proteins, there is no direct evidence that these proteins are capable
of restricting mRNA synthesis from the HSV genome. Likewise, it
has been postulated that epigenetic silencing may be the ICP0-
antagonized repressive mechanism that is capable of silencing the
HSV genome [20,55]. However, no specific histone deacetylase or
histone mark has been associated with more than a 2-fold
reduction in HSV mRNA synthesis [18,19,56,57].
Although an ICP0-antagonized repressor has not been
identified, it would be reasonable to expect that the repressive
entity: 1. should be necessary and sufficient to restrict the synthesis
of one or more HSV mRNAs; 2. should be unable to silence HSV
mRNA synthesis when ICP0 accumulates; and 3. may physically
interact with ICP0. The results of the current study establish that
HSV’s major transcriptional regulator, ICP4, meets these criteria,
and thus appears to be the first bona fide ICP0-antagonized
repressor of HSV mRNA synthesis.
The results clarify that ICP4 is capable of silencing mRNA
synthesis from the ICP0 gene when ICP0 fails to accumulate. At
low MOIs, HSV ICP0
2 viruses establish quiescent infections in
99% of infected cells [9,10]. Intriguingly, ICP4 accumulates to
detectable levels in .85% of cells that become quiescently infected
with HSV ICP0
2 viruses [58]. Thus, further studies will be
required to determine if ICP4 routinely accumulates in the
absence of ICP0 in HSV quiescently infected cells, and if so, to
determine if ICP4 plays a causal role in restricting mRNA
synthesis from quiescent HSV genomes [59,60,61].
Differential Regulation of ICP0 mRNA Synthesis in
HSV-Infected Cells
There is anecdotal evidence that the ICP0 gene is differentially
regulated in HSV-infected cells, but it remains unclear how such
regulation is achieved. The HSV latency-associated transcripts
(LATs) have been discussed for their potential to repress ICP0 gene
expression [62,63]. Likewise, VP16’s capacity to function as a
transactivator of IE genes has been considered as a potential target
of differential regulation [64,65,66]. However, it remains unclear
that LATs or VP16 are sufficient to explain how the ICP0 gene is
regulated.
The ICP4-binding site in the ICP0 promoter was identified 20
years ago as a potential means by which ICP4 might regulate
ICP0 mRNA synthesis [51]. When studied in the context of HSV
ICP0
+ viruses, some investigators concluded that ICP4’s effect on
ICP0 gene expression was negligible [36]. Other investigators
noted that ICP4 produced a modest decrease in ICP0 mRNA
levels in the context of ICP0
+ viruses [37], but ICP4’s full potential
to silence ICP0 gene expression went unrecognized.
The current study demonstrates that the ICP0 gene is
differentially regulated by three HSV proteins, VP16, ICP4, and
Figure 8. Exogenous ICP4 substitutes for the de novo repressor
of the ICP0
2GFP gene. Representative Northern blots of ICP0
2GFP
mRNA levels in Vero cells treated with 200 mM cycloheximide and
inoculated with 5 pfu per cell of (A) HSV-1 0
2GFP or (B) HSV-1 0
24BS
2
(10 mg total RNA per lane; time of harvest=12 hours p.i.). Twelve hours
prior to HSV-1 inoculation, cells were pre-treated with 0, 10, 50, or 250
pfu per cell of Ad-ICP4 or Ad-null whose TRE promoters were induced
with 20 pfu per cell of Ad.CMV-TetOn and 10 mM doxycycline. (C) Mean
6 sem fold-reduction in ICP0
2GFP mRNA levels in HSV-1 0
2GFP or
0
24BS
2 infected cells as a function of the MOI of Ad-ICP4 in the pre-
treatment (n=3 per group). Asterisks denote significant differences in
Ad-ICP4-induced reductions in ICP0
2GFP mRNA levels between HSV-1
0
2GFP and 0
24BS
2 (p,0.001; two-way analysis of variance).
doi:10.1371/journal.pone.0008837.g008
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to be fully resolved. Functionally, the results suggest that VP16 and
ICP4 ‘push’ ICP0 mRNA synthesis in opposite directions, and
accumulation of ICP0 dictates which way this equilibrium will tilt.
When ICP0 fails to accumulate, ICP4 is capable of silencing ICP0
mRNA synthesis despite VP16 in the tegument of virions (Fig. 3–6;
ICP0
2 treatments). When formation of the de novo repressor is
blocked with cycloheximide, VP16’s full capacity to transactivate
the HSV-1 ICP0 gene is revealed (Fig. 5). If ICP0 accumulates,
ICP4 fails to efficiently repress ICP0 mRNA synthesis (Fig. 3–6;
ICP0
+ treatments). These findings suggest that a hierarchy exists in
the HSV regulatory scheme in which i. ICP0-dependent
antirepression of the ICP0 gene is dominant over ii. ICP4-
dependent repression of the ICP0 gene, which is dominant over
iii. VP16-dependent induction of the ICP0 gene. Therefore, while
VP16 induces transcription of both the ICP4 and ICP0 genes, the
opposing processes of ICP4-dependent repression and ICP0-
dependent antirepression appear to dictate whether the ICP0 gene
remains ON or OFF in HSV-infected cells (Fig. 3B).
ICP4-Dependent Silencing of the ICP0 Gene: A Cell
Type-Specific Phenomenon?
Less than 1 HSV ICP0
2 virus per 10,000 pfu is able to form
plaques in monolayers of HEL cells [67]. In contrast, 1 HSV
ICP0
2 virus per 100 pfu forms plaques in Vero cell monolayers
[9], and nearly 100% of HSV ICP0
2 viruses form plaques in
U2OS cell monolayers [52]. The highly variable permissivity of
host cells for HSV ICP0
2 viruses raises the question, ‘‘Is ICP4’s
capacity to silence ICP0 gene expression in Vero cells representative of what
occurs in other cell types?’’ Therefore, it is noteworthy that HSV
ICP0
2 viruses form plaques with an efficiency that is indistin-
guishable from Vero cells in 11 of 15 other cell lines tested to date.
Specifically, 0.5–2% of HSV ICP0
2 viruses form plaques in
monolayers of human 293 cells, mouse 3T3 cells, hamster BHK-
21 cells, bovine BIEC cells, bovine BUVEC cells, human Caco-2
cells, human HeLa cells, monkey MA104 cells, canine MDCK
cells, pig PK-15 cells, and human WiDr cells (unpublished data of
W. Halford). Further testing will be required to determine if the
phenomenon of ICP4-dependent silencing of the ICP0 gene varies
in proportion to the degree with which HSV ICP0
2 viral
replication is restricted in different cell lines.
ICP0 as a Regulatory Subunit of ICP4: A Missing Lynchpin
in HSV Gene Regulation?
The 1298-amino-acid ICP4 protein functions as an essential
activator that recruits cellular TATA-binding protein complexes to
HSV genomes, and thus stimulates mRNA synthesis from HSV E
and L genes [46]. ICP4 also possesses a second activity as a
repressor of HSV IE genes, which requires the binding of 350 kDa
ICP4 homodimers to consensus ATCGTC sequences [68,69]. To
date, it remains unclear how the balance between ICP4’s opposing
transcriptional repressor versus activator functions is controlled.
Since the discovery that ICP0 re-organizes PML nuclear bodies
[29], ICP4 and ICP0 have been predominantly studied in isolation
from one another. However, ICP0 was initially discovered as a
factor that stimulated a 20-fold increase in ICP4-dependent
mRNA synthesis from HSV E and L promoters [6]. The results of
the current study establish that ICP0 and ICP4 participate in a
robust physical interaction in HSV-infected cells (Fig. 9). We
postulate that ICP0’s physical interaction with ICP4 is likely
regulatory in nature, and hence may be relevant in explaining how
ICP0 potentiates ICP4-dependent E and L mRNA synthesis [5,6],
Figure 9. ICP4 co-immunoprecipitates with FLAG-tagged ICP0. (A) Schematic of 30-bp insertion in the HSV-1 recombinant virus, 0
+FLAG24,
which places a FLAG tag coding sequence between codons 23 and 24 of the ICP0 gene. (B and C) Vero cells were inoculated with 5 pfu per cell of
HSV-1 KOS (wild-type) or HSV-1 0
+FLAG24, which were treated with 200 mM cycloheximide from 20.5 to 10 hours p.i., released into actinomycin D
(10 mg/ml) from 10 to 16 hours p.i., and harvested for immunofluorescent staining or immunoprecipitation. (B) Immunofluorescent staining with a
FLAG-specific antibody and AlexaFluor 594-conjugated secondary antibody. (C) Cells were harvested in an NP40-based buffer containing 150 mM
NaCl (left panel) or RIPA buffer (right panel). The relative abundance of ICP4 and ICP0 was compared in 5% of total cell lysates (top panel), and the
remainder was immunoprecipitated with anti-FLAG agarose. Immunoprecipiates were washed in 500 mM NaCl (left panel) or RIPA buffer (right panel)
prior to electrophoresis and blotting, and were probed with ICP4-specific monoclonal antibody 58S (middle panel), followed by re-probing with ICP0-
specific monoclonal antibody H1083 (bottom panel). The relative locations of ICP4 and ICP0 are denoted by asterisks and open circles, respectively.
doi:10.1371/journal.pone.0008837.g009
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ICP0 mRNA synthesis (Fig. 3–5). Therefore, we propose that the
accumulation of ICP0 in HSV-infected cells (or lack thereof) may
dictate whether ICP4 functions predominantly as an activator, or
a repressor, of HSV mRNA synthesis. Further studies will be
required to test the validity of this important hypothesis.
How Does ICP0 Antagonize ICP4-Dependent Repression?
What specific protein-DNA complexes explain how ICP0
antagonizes ICP4-dependent silencing of the ICP0 gene? The
mechanisms that underlie the phenomenon documented herein
are unknown, and further study will be required to differentiate
between many possibilities. To illustrate this point, we present two
molecular models that are each consistent with our findings, but
which suggest two completely different interpretations for the
significance of an interaction between ICP0 and ICP4 in the
biology of HSV infections.
The first model, the ICP0-ICP4 Interference Model, is the most
intuitively obvious interpretation and may reflect the mental
model that many readers have invoked up to this point in the
manuscript to make sense of the results. Under an ICP0-ICP4
Interference Model, it could be predicted that 1. ICP4 binding to
HSV dsDNA serves the sole purpose of repressing mRNA
synthesis from adjacent HSV genes, and that 2. ICP0 blocks
ICP4’s capacity to bind dsDNA, and thus ICP0 blocks ICP4-
dependent repression of the HSV ICP0 gene. However, synthesis
of ICP4 is required for synthesis of viral E and L mRNAs, and
mutations that disrupt ICP4’s DNA-binding domain also render
HSV incapable of synthesizing its ,70 E and L mRNAs that are
required for HSV replication [50,70,71]. Therefore, it is difficult
to envision how an ICP0-based activity that dislodges ICP4 from
dsDNA would help explain how ICP0 potentiates ICP4-dependent
synthesis of HSV E and L mRNAs [5,6].
An ICP0-ICP4 Synergy Model is less intuitively obvious, but is
more consistent with ICP0’s capacity to enhance ICP4-dependent
synthesis of HSV E and L mRNAs. Under this latter model, it may
be envisioned that 1. the functional purpose of ICP4 and the .50
ICP4-binding sites that span the HSV genome is to allow ICP4 to
form a histone-like scaffold that coats HSV genomes; 2. the 1298
amino-acid ICP4 protein possesses numerous domains that allow
ICP4 to interact with cellular proteins [72,73] and viral proteins
(Fig. 9) which influence whether ICP4 stimulates or represses
mRNA synthesis from the underlying HSV DNA; and 3. the
nature of ICP0’s interaction with ICP4 relates to potentiating
ICP4-dependent activation of mRNA synthesis from HSV DNA.
Clearly, further investigation will be required to determine if the
specific protein-DNA interactions that occur in HSV-infected cells
are consistent with an ICP0-ICP4 Synergy Model of HSV gene
regulation.
Conclusion
The herpesviruses and temperate bacteriophage are large
dsDNA viruses that share the capacity to alternate between
productive and silent infections. Many similarities have emerged in
the mechanisms that herpesviruses and the tailed bacteriophage
employ to replicate and encapsidate their large dsDNA genomes
[74,75,76,77]. Such observations point to a common evolutionary
ancestry between these two ancient families of viruses [78,79]. We
conclude that the results of the current study appear to add to this
growing list of inexplicable similarities.
The parallel capacity of HSV and bacteriophage l to alternate
between productive and silent infections may not be a coincidence.
Rather, both viruses may control the onset of viral replication
through a system of repression and antirepression of a few IE
proteins whose accumulation, or lack thereof, dictates the
probability of replication. In l phage, the ‘decision’ between
productive versus silent infections hinges upon whether the l cro
antirepressor gene is expressed or repressed [80,81,82]. Thus,
important questions follow from the observation that HSV
encodes its own transcriptional repressor function, embedded in
ICP4, which is capable of silencing the HSV antirepressor gene that
encodes ICP0. Further study will be required to determine if, in
fact, repression-antirepression of the ICP0 gene is relevant to the
natural process by which HSV ‘decides’ whether a given infection
will be productive or silent.
Materials and Methods
Cells and Viruses
Vero cells and 293 cells were obtained from the American Type
Culture Collection (Manassas, VA). ICP4-complementing E5 and
ICP0-complementing L7 cell lines were kindly provided by Neal
Deluca (University of Pittsburgh; Ref. [83]). ICP27-complement-
ing V27 cells and HSV-1 d27-1 (ICP27
2) virus were a kind gift of
Steve Rice (University of Minnesota Medical School, Minneapolis;
Ref. 48). Cell lines were propagated in Dulbecco’s Modified
Eagle’s medium supplemented with 5% fetal bovine serum and
antibiotics.
Table 1 summarizes the HSV-1 recombinant viruses used in
this study, which are derivative of low passage strains of wild-type
HSV-1 strain KOS [84]. HSV-1 KOS, HSV-1 22/n199 (ICP22
2;
Ref. 49), HSV-1 0
+GFP (ICP0
+GFP), and HSV-1 0
+4BS
2
(ICP0
+GFP) were propagated in Vero cells. The HSV-1 ICP4
2
virus n12 [50] and the ICP4 temperature-sensitive virus HSV-1
tsB21 [47] were propagated in ICP4-complementing E5 cells. The
HSV-1 ICP0
2 viruses n212 [43], 0
2GFP (ICP0
2GFP), and 0
24BS
2
(ICP0
2GFP) were propagated and titered in ICP0-complementing
L7 cells, as was the HSV-1 VP16
2 virus RP4 [44] that was kindly
provided by Steve Triezenberg (Michigan State University, East
Lansing).
The salient features of each mutation in the ICP0 gene are
summarized, as follows: i. the HSV-1 ICP0
2 null virus n212
contains a 14 bp translational stop insertion (ctagactagtctag) in
codon 212 of the ICP0 gene; hence, the n212 virus encodes the N-
terminal 211 of 775 amino acids of ICP0 [43]; ii. the HSV-1
ICP0
2 null viruses 0
2GFP and 0
24BS
2 each contain a GFP open-
reading frame and translational stop inserted in codon 105 of the
ICP0 gene; hence, HSV-1 0
2GFP and 0
24BS
2 encode the N-
terminal 104 amino acids of ICP0 fused to GFP; and iii. the HSV-
1 ICP0
+ viruses 0
+GFP and 0
+4BS
2 each encode a chimeric
protein in which GFP is inserted between amino acids 104 and
105 of ICP0.
Table 2 summarizes the DE1–DE3 adenovirus vectors used in
this study, which were propagated in human embryonic kidney
293 cells in complete DMEM, as described previously [7].
Adenovirus titers were determined by a limiting dilution analysis
in 96-well cultures of 293 cells to establish the titer of infectious
virus in terms of 50% tissue-culture infectious dose (TCID50). One
TCID50 unit is equivalent to 1 pfu, but the TCID50 assay is less
prone to underestimate adenovirus vector titers (unpublished data
of W. Halford).
Plasmid Precursors of HSV-1 Recombinant Viruses
The construction of plasmid precursors of the HSV-1
recombinant viruses used in this study is described. A 7.3 kb
DNA fragment which encompasses the entire LAT-ICP0 locus
(118,003–125,269; accession number X14112) was subcloned
from HSV-1 (strain KOS) into a pCRII plasmid vector (Invitrogen
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subcloned into this plasmid, pCRII-HSV118-125, and plasmids
bearing the desired mutation were co-transfected with HSV-1
strain KOS to obtain each of the recombinant viruses described
below. The mutagenesis steps taken to create each mutant allele of
the ICP0 gene are summarized, as follows.
i. p0
2 GFP: The plasmid p0
2GFP was created by a multi-step
sub-cloning procedure, which inserted a polylinker, GFP
coding sequence, and stop codon derived from the plasmid
peGFP-N1 (Clontech Laboratories) into a Xho I site in
codon 104 of the ICP0 gene. The resulting plasmid, p0
2GFP,
encoded the N-terminal 104 amino acids of ICP0 fused to
GFP by a 14-amino-acid linker. Homologous recombination
between HSV-1 KOS and the plasmid p0
2GFP yielded the
recombinant virus HSV-1 0
2GFP (Table 1).
ii. p0
+ GFP: The plasmid p0
+GFP was derived by subcloning a
dsDNA linker containing BsrGI and Xho I sites (tgtaca
agatat ctcgag) into the 39 end of the GFP coding sequence in
p0
2GFP. This sub-cloning step deleted 7 bp, thus removing
a TAA terminator codon and placing the GFP and ICP0
coding sequences in the same open-reading frame. The
resulting plasmid, p0
+GFP, encoded the ICP0
+GFP reporter
protein, which bears a GFP insertion between amino acids
104 and 105 of ICP0. Homologous recombination between
HSV-1 KOS and p0
+GFP yielded the recombinant virus
HSV-1 0
+GFP (Table 1).
iii. p0
2 4BS
2 and p0
+ 4BS
2: The plasmids p0
24BS
2 and
p0
+4BS
2 were created as follows. A plasmid, pmin0
2GFP,
contains the ICP0 promoter region and a unique Tfi I
restriction site that overlaps the ICP4 DNA-binding site
(4BS) element in the ICP0 promoter. Thus, mutation of the
4BS element was achieved by linearizing pmin0
2GFP with
Tfi I, using mung bean exonuclease to remove ssDNA
overhangs, and religating with T4 DNA ligase. The 4-bp
deletion in the 4BS element was confirmed by the loss of the
Tfi I restriction site and DNA sequencing (Fig. 7A). The
ICP4-binding site mutation was transferred into the larger
plasmids p0
2GFP and p0
+GFP by subcloning a Xho I -
EcoRI restriction fragment to yield the plasmids p0
24BS
2
and p0
+4BS
2. Homologous recombination between HSV-1
KOS and these plasmids yielded the HSV-1 recombinant
viruses 0
24BS
2 and 0
+4BS
2 (Table 1).
iv. p0
+FLAG24: The plasmid p0
+FLAG24 was created as
follows. A plasmid, p0
+GFP24, contained a Bgl II restriction
site-GFP coding sequence-Spe I restriction site insertion
between amino acids 23 and 24 of the ICP0 open-reading
frame. A dsDNA oligonucleotide linker of the following
sequence was synthesized, CCCAGATCTGGACTA-
CAAGGACGATGACGACAAACTAGTCTG, digested
with Bgl II and Spe I, and subcloned in place of the GFP
sequence to create p0
+FLAG24. The resulting gene encoded
a FLAG-tagged protein that bore the amino acid sequence
LDYKDDDDKL between amino acids 23 and 24 of ICP0.
Homologous recombination between HSV-1 KOS and
p0
+FLAG24 yielded the HSV-1 recombinant virus
0
+FLAG24 (Table 1).
Construction of Recombinant HSV-1 Viruses
Infectious HSV-1 DNA was prepared by a protocol that relies
upon dialysis to minimize shearing of genome-length HSV-1
DNA; this is a modification of a protocol that was generously
provided by Karen Mossman (McMaster University, Hamilton,
Ontario). Five 100 mm dishes of Vero cells (3610
7 cells) were
inoculated with 5 pfu per cell of HSV-1 strain KOS. After
24 hours, cells were scraped, centrifuged, rinsed with PBS,
resuspended in 7.0 ml of 200 mM EDTA pH 8.0, and transferred
into a 15 ml conical. Proteinase K (75 ml of 10 mg/ml) and 375 ml
of 10% SDS were added to virus-infected cells, and the tube was
incubated in a rotisserie (hybridization) oven with slow rotation at
50uC for 16 hours. Proteins were removed by phenol : chloroform
extraction, DNA was transferred into a 0.5–3.0 mL Slide-a-lyzer
cassette (10,000 MW cutoff; Pierce Chemical Co., Rockford, IL),
dialyzed against 0.16 standard saline citrate for 24 hours,
aliquoted and frozen at 280uC until use.
Recombinant HSV-1 viruses were generated by co-transfecting
the following DNA species into a 60 mm dish containing 8610
5
ICP0-complementing L7 cells: 1. 1.8 mg infectious HSV-1 KOS
DNA, 2. 0.2 mg of an ICP0-expressiong plasmid (which promotes
HSV-1 replication), and 3. 1.0 mg of each ICP0
GFP reporter gene
plasmid described above. Lipofectamine 2000 (Invitrogen Corpo-
ration) was used as the transfection reagent. After 12 hours,
co-transfection medium was replaced with complete DMEM
containing 1% methylcellulose and GFP
+ plaques were selected on
the stage of a TE2000 fluorescent microscope (Nikon Instruments,
Lewisville, TX). GFP
+ recombinant viruses were repeatedly passed
in ICP0-complementing L7 cells until a uniform population of
viruses was obtained that produced 100% GFP
+ plaques, at which
time Southern blot analysis was used to confirm that the
anticipated ICP0
GFP reporter gene was transferred into the HSV-
1 recombinant virus.
Western Blot Analysis
Vero cell cultures were established at a density of 3610
5 cells
per well in 12-well plates, and were infected at an MOI of 5 pfu
per cell. After 18 hours, proteins were harvested using mammalian
protein extraction reagent (Pierce Chemical Co., Rockford, IL)
supplemented with 1 M dithiothreitol and protease inhibitor
cocktail set I (Calbiochem, La Jolla, CA). After heat denaturation,
20 mg of each protein sample and MagicMark
TM XP protein MW
markers (Invitrogen, Carlsbad, CA) were resolved in a 10%
polyacrylamide gel with a 4% stacking gel, and were transferred to
nitrocellulose membranes. Protein blots were blocked in phos-
phate-buffered saline (PBS) containing 5% nonfat dry milk, and
were incubated overnight at 4uC in PBS +0.1% Tween-20 +5%
nonfat dry milk containing a 1:1000 dilution of primary anti-
bodies. Specifically, the primary antibodies were either the mouse
monoclonal 11060 antibody specific for a peptide between amino
acids 20 to 105 of ICP0 (Santa Cruz Biotechnology, Santa Cruz,
CA; Ref. [85]), mouse monoclonal H1083 antibody specific for a
peptide between amino acids 395 to 775 of ICP0 (EastCoast Bio,
North Berwick, MA; Ref. [86]), mouse monoclonal 58S antibody
specific for a peptide between amino acids 700 to 1298 of ICP4
(Santa Cruz Biotechnology Clone 10F1; Ref. [87]), or a rabbit
polyclonal anti-GFP antibody (Clontech Laboratories Inc.).
Following incubation with primary antibodies, membranes were
washed four times with PBS +0.1% Tween-20 (PBS-T), and were
then incubated for 1 hour with secondary antibodies diluted
1:20,000 in PBS +0.1% Tween-20 + nonfat 5% dry milk. The
secondary antibodies were goat anti-rabbit IgG and goat anti-
mouse IgG that were respectively conjugated to the infrared
fluorescent dyes IRDyeH 680 and IRDyeH 800CW (LI-COR
Bioscience, Lincoln, NE). Protein blots were washed three times in
PBS-T, rinsed in PBS (to remove Tween-20), and were scanned
for two-color fluorescence using the Odyssey Infrared imaging
system (LI-COR Bioscience). Data were analyzed using Odyssey
application software version 3.0.16 (LI-COR Bioscience).
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Cultures of L7 or Vero cells were established at a density of
1.5610
6 cells per plate in 60 mm dishes, and inoculated with MOIs
of 0.1 to 5 pfu per cell. RNA was isolated using Ultraspec RNA
isolation reagent (Biotecx Inc., Houston, TX). Equal amounts of
total RNA (10 mg) were electrophoretically separated on 1%
formaldehyde agarose gels, blotted onto Zeta Probe GT nylon
membranes (Biorad Laboratories, Hercules, CA), and hybridized
with radiolabeled oligonucleotides specific for exon 3 of HSV-1
ICP0 mRNA (59-ggagtcgctgatcactatggggtctctgttgtttgcaagg-39), GFP
mRNA (59-atagacgttgtggctgttgtagttgtactccagcttgtgc-39), HSV-1 gly-
coprotein D mRNA (59-aggcccccagagacttgttgtaggagcattcggtgtactc-
39) or cellular GAPDH mRNA (59-tgaccttggccaggggtgctaagcag-
ttggtggtgcagga-39). Oligonucleotides were end-labeled with [a-
32P]
dATP using terminal deoxynucleotidyl transferase (Promega
Corporation, Madison, WI) and were hybridized to their target
sequence via 16 hours of hybridization at 37uC in a solution
containing 5 ng/ml labeled probe, 7% SDS, 120mM NaH2PO4,
and 250mM NaCl. Excess probe was removed from membranes by
sequential rinses in 0.16 standard saline citrate containing 0.1%
SDS. Blots were exposed to phosphor screens, which were scanned
and analyzed with a Cyclone PhosphorImager and OptiQuant
software (Perkin Elmer, Boston, MA).
Drug Treatments
In all experiments in which cycloheximide was used, 200 mM
cycloheximide (Sigma Chemical Co., St. Louis, MO) was added to
Vero cells 30 minutes prior to HSV-1 inoculation, and was
maintained in cultures until the time of RNA harvest, or until the
time at which protein translation was restored by removing
cycloheximide, rinsing cultures twice, and thereafter incubating
cells in complete DMEM containing 10 mg/ml actinomycin D
(Sigma Chemical Co.).
Immunofluorescent Staining of HSV-Infected Cells
The subcellular localization of FLAG-tagged ICP0 in HSV-1
0
+FLAG24-infected cells was determined using an adaptation of a
staining protocol that was generously provided by Roger Everett
(MRC Virology Unit, Glasgow, Scotland). Cells were fixed with
PBS containing 2% formaldehyde and 2% sucrose for 10 minutes
and were permeabilized with 90% methanol for 10 minutes.
HSV-1 Fc-c receptors (glycoprotein E-I heterodimers; Ref. [88])
were blocked along with all other non-specific protein-binding sites
by incubating fixed cells in a solution of PBS containing 0.5% fetal
bovine serum and 10 mg/ml each of the c-globulin fractions of
human, donkey, and goat serum (PBS-F-Ig). Fixed and blocked
cells were incubated for 16 hours with a 1:1000 dilution of mouse
FLAG-specific mouse monoclonal FLAG-M2 antibody (Sigma
Chemical Co.). Excess antibody was removed by washing with
PBS-F-Ig solution, and cells were incubated for 1 hour in 1:1000
Alexa Fluor 594-conjugated goat a-mouse IgG secondary
antibody (Molecular Probes, Eugene, OR). Excess secondary
antibody was removed by washing with PBS-F-Ig solution, and
cells were photographed at 206 magnification using a TE2000
inverted fluorescent microscope (Nikon Instruments, Lewisville,
TX) and an Olympus DP72 digital camera (Olympus America
Inc., Center Valley, PA).
Co-Immunoprecipitation of FLAG-Tagged ICP0 and ICP4
Replicate 100 mm dishes containing 10
7 Vero cells were
inoculated with vehicle or 5 pfu per cell of HSV-1 KOS or
HSV-1 0
+FLAG24 in the presence of 200 mM cycloheximide. At
10 hours p.i., cycloheximide-containing medium was replaced
with 10 mg/ml actinomycin D, and 6 hours was allowed for
translation of accumulated IE mRNAs. At 16 hours p.i., 100 mm
dishes of Vero cells were washed with ice-cold phosphate-buffered
saline, and cells were lysed in either 0.5 ml of an NP40-based
buffer or RIPA buffer. The NP40-based buffered contained
50 mM Tris (pH 7.4), 150 mM sodium chloride, 2 mM EDTA,
1% NP40, and 16 Halt protease inhibitor cocktail (Pierce
Chemical Co.). RIPA buffer consisted of 50 mM Tris (pH 8.0),
150 mM sodium chloride, 1% NP40, 0.5% sodium deoxycholate,
0.1% SDS, and 16 Halt protease inhibitor cocktail. Cell lysates
were incubated for 2 hours at 4uC on a rotisserie, cell debris was
removed by centrifugation, and 10% of each lysate was reserved
for Western blot comparison of relative levels of ICP0 and ICP4.
Supernatants were pre-cleared by incubation with 1 mg normal
mouse IgG and Protein A/G agarose beads (SantaCruz
Biotechnology) for 30 min at 4uC. Pre-cleared supernatants were
incubated with 15 ml of FLAG-M2 agarose beads (Sigma
Chemical Company) overnight at 4uC. Immunocomplexes were
washed four times with NP-40 buffer containing 500 mM NaCl
or RIPA buffer, and were prepared for Western blot analysis by
boiling in 26Laemmli loading buffer prior to electrophoresis on
an 8% polyacrylamide gel. Transfer and detection of blotted
proteins on PVDF membranes was performed as described
above.
Supporting Information
Figure S1 Quantitative comparison of the accumulation of
ICP0
2GFP and ICP0
+GFP protein accumulation following
cycloheximide release. (A and B) Photomicrographs of Vero cells
infected with 2.5 pfu per cell of (A) HSV-1 0
2GFP or (B) HSV-1
0
+GFP at 6, 12, and 18 hours p.i., as visualized by fluorescence
microscopy (206 magnification). Vero cells were treated with
vehicle or 200 A ˆmM cycloheximide (CHX) from 20.5 to 6 hours
p.i. (red box denotes CHX treatment), and cultures were released
into medium containing no inhibitor from 6 to 18 hours p.i. (C)
ICP0
GFP protein abundance between 3 and 18 hours p.i., as
determined by flow cytometry. Each point represents the mean 6
sem of ICP0
GFP abundance in n=3 cultures x n=25,000 cells per
culture, where protein abundance was defined as the mean GFP
fluorescence intensity scaled relative to background fluorescence, as
defined by n=12 uninfected cultures. The details of this
methodology for quantifying GFP fluorescence are described in
detail elsewhere [40].
Found at: doi:10.1371/journal.pone.0008837.s001 (6.67 MB TIF)
Figure S2 Replicate blots of HSV-1 0
2GFP and 0
+GFP RNA
samples shown in Figure 4 probed for (A) HSV-1 glycoprotein D
mRNA or (B) cellular GAPDH mRNA, which encodes the
glycolytic enzyme glyceraldehyde 3-phosphodehydrogenase. RNA
was harvested from uninfected Vero cells (0 hours) or from cells
between 3 and 12 hours after inoculation with 2.5 pfu per cell of
HSV-1 0
2GFP or HSV-1 0
+GFP. Cells were treated with vehicle
or 200 mM cycloheximide until the indicated time of total RNA
harvest (10 mg per lane).
Found at: doi:10.1371/journal.pone.0008837.s002 (7.21 MB TIF)
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